Skip to main content

Advertisement

SpringerLink
Log in

Biliary tract inflammatory disorders: Primary sclerosing cholangitis and primary biliary cirrhosis

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) are chronic progressive cholestatic diseases that frequently lead to biliary cirrhosis. The exact pathogenesis of these diseases remains elusive but is likely immunologically based. Complications range from fatigue and pruritus to end-stage liver disease. The risk of developing hepatocellular carcinoma is low for patients with PBC, whereas cholangiocarcinoma is common in PSC and carries an ominous prognosis. Although ursodeoxycholic acid is effective in slowing the progression of PBC, no effective medical therapy exists for PSC. Liver transplantation is the only option for patients with endstage liver disease and yields excellent long-term survival in both groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chapman RW, Varghese Z, Gaul R, et al.: Association of primary sclerosing cholangitis with HLA-B8. Gut 1983, 24:38–41.

    Article  PubMed  CAS  Google Scholar 

  2. Schrumpf E, Fausa O, Fore O, et al.: HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982, 17:187–191.

    Article  PubMed  CAS  Google Scholar 

  3. Donaldson PT, Farrant JM, Wilkinson ML, et al.: Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991, 13:129–133.

    Article  PubMed  CAS  Google Scholar 

  4. Seibold R, Weber P, Schoning A, et al.: Neutrophil antibodies (pANCA) in chronic liver disease: do they react with different antigens? Eur J Gastroenterol Hepatol 1996, 8:1095–1100.

    Article  PubMed  CAS  Google Scholar 

  5. Schrumpf E, Fausa O, Elgio K, et al.: Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988, 8:201–209.

    Article  PubMed  CAS  Google Scholar 

  6. Wiesner RH, Grambsch PM, Dickson ER, et al.: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430–436.

    Article  PubMed  CAS  Google Scholar 

  7. Ludwig J, Barham SS, LaRusso NF, et al.: Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981, 1:632–640.

    Article  PubMed  CAS  Google Scholar 

  8. Finegold MJ, Carpenter RJ: Obliterative cholangitis due to cytomegalovirus: a possible precursor of paucity of intrahepatic bile ducts. Hum Pathol 1982, 13:662–665.

    Article  PubMed  CAS  Google Scholar 

  9. Holzbach RT, Marsh ME, Freedman MR, et al.: Portal vein bile acids in patients with severe inflammatory bowel disease. Gut 1980, 21:428–435.

    Article  PubMed  CAS  Google Scholar 

  10. Dew MJ, van Berge Henegouwen GP, Huybregts AW, et al.: Hepatotoxic effect of bile acids in inflammatory bowel disease. Gastroenterology 1980, 78:1393–1401.

    PubMed  CAS  Google Scholar 

  11. Gross JB Jr, Ludwig J, Wiesner RH, et al.: Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985, 89:272–278.

    PubMed  Google Scholar 

  12. Bergquist A, Broomé U: Clinical features in primary sclerosing cholangitis. Clin Liver Dis 1998, 2:283–301.

    Article  PubMed  CAS  Google Scholar 

  13. Brandt DJ, MacCarty RL, Charboneau JW, et al.: Gallbladder disease in patients with primary sclerosing cholangitis. Am J Roentgenol 1988, 150:571–574.

    CAS  Google Scholar 

  14. Aadland E, Schrumpf E, Fausa O, et al.: Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1997, 22:655–664.

    Article  Google Scholar 

  15. Farrant JM, Hayllar KM, Wilkinson ML, et al.: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710–1717.

    PubMed  CAS  Google Scholar 

  16. Rosen CB, Nagorney DM: Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991, 11:26–30.

    Article  PubMed  CAS  Google Scholar 

  17. Broomé U, Olsson R, Loof L, et al.: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610–615. In this study, 305 patients with PSC were followed for a median of 63 months. Multivariate analyses were used to evaluate key end points, including liver transplantation, development of cholangiocarcinoma, and death.

    Article  PubMed  Google Scholar 

  18. Carson KL, Tran TT, Cotton P, et al.: Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996, 91:1022–1023.

    PubMed  CAS  Google Scholar 

  19. Bohorfoush A, Franco J, Komorowski R, et al.: Flow cytometric analysis of bile duct epithelium in primary sclerosing cholangitis potentially assists timing of liver transplantation. Gastrointest Endosc 1997, 45:1858A.

    Article  Google Scholar 

  20. Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group: Urosodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336:691–695. This randomized double-blind study evaluated the effectiveness of UDCA in the treatment of PSC. End points addressed included biochemical, histologic, and clinical deterioration; the need for liver transplantation; and death.

    Article  PubMed  CAS  Google Scholar 

  21. Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 30 year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57–64.

    Article  PubMed  CAS  Google Scholar 

  22. Olsson R, Broomé U, Danielsson A, et al.: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995, 108:1199–1203.

    Article  PubMed  CAS  Google Scholar 

  23. LaRusso NF, Wiesner RH, Ludwig J, et al.: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988, 95:1036–1042.

    PubMed  CAS  Google Scholar 

  24. Knox TA, Kaplan MM: A double-blind controlled trial of oralpulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994, 106:494–499.

    PubMed  CAS  Google Scholar 

  25. Lindor KD, Wiesner RH, Colwell LJ: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991, 85:57–61.

    Google Scholar 

  26. Kyokane K, Ichihara T, Horisawa M, et al.: Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994, 41:449–452.

    PubMed  CAS  Google Scholar 

  27. Van Thiel DH, Carroll P, Abu-Elmagd K, et al.: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455–459.

    PubMed  Google Scholar 

  28. Wiesner RH, Brambsch PM, Dickson ER, et al.: Primary sclerosing cholangitis: natural history, prognostic factors, and survival analysis. Hepatology 1989, 10:430–436.

    Article  PubMed  CAS  Google Scholar 

  29. Dickson ER, Murtaugh PA, Wiesner RH, et al.: Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992, 103:1893–1901.

    PubMed  CAS  Google Scholar 

  30. Farrant JM, Hayllar KM, Wilkinson ML, et al.: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710–1717.

    PubMed  CAS  Google Scholar 

  31. Neuberger J: Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transplant Surg 1995, 1(suppl 5):109–115.

    CAS  Google Scholar 

  32. Metcalf J, Howel D, James O, et al.: Primary biliary cirrhosis: epidemiology helping the clinician. BMJ 1996, 312:1181–1182.

    PubMed  CAS  Google Scholar 

  33. Witt-Sullivan H, Heathcote EJ, Cauch K, et al.: The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990, 12:98–105.

    Article  PubMed  CAS  Google Scholar 

  34. Bach N, Schaffner F: Familial primary biliary cirrhosis. J Hepatol 1994, 20:698–701.

    Article  PubMed  CAS  Google Scholar 

  35. Cauch-Dudek K, Abbey S, Stewart DE, et al.: Fatigue and quality of life in primary biliary cirrhosis. Hepatology 1995, 22:108A.

    Google Scholar 

  36. Crippin JF, Lindor KD, Jorgensen R, et al.: Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992, 15:858–862.

    Article  PubMed  CAS  Google Scholar 

  37. Navasa M, Pares A, Brugera M, et al.: Portal hypertension in primary biliary cirrhosis: relationship with histological features. J Hepatol 1987, 5:292–298.

    Article  PubMed  CAS  Google Scholar 

  38. Melia WM, Johnson PJ, Neuberger J, et al.: Hepatocellular carcinoma in primary biliary cirrhosis: detection by alphafetoprotein estimation. Gastroenterology 1984, 87:660–663.

    PubMed  CAS  Google Scholar 

  39. Gershwin ME, Mackay IR, Sturgess A, et al.: Identification and specificity of a cDNA encoding the 70-kDa mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987, 138:3525–3531.

    PubMed  CAS  Google Scholar 

  40. Yeaman SJ, Fussey SPM, Danner DJ, et al.: Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988, 1:1067–1070.

    Article  PubMed  CAS  Google Scholar 

  41. Heathcote EJ: The clinical expression of primary biliary cirrhosis. Semin Liver Dis 1996, 17:23–33. The author presents a concise review of the clinical presentation of primary biliary cirrhosis and its associated extrahepatic disorders.

    Article  Google Scholar 

  42. Scheuer PJ: Primary biliary cirrhosis. Proc R Soc Med 1967, 60:1257–1260.

    PubMed  CAS  Google Scholar 

  43. Ludwig J, Dickson ER, McDonald GSA: Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch 1978, 379:103–112.

    CAS  Google Scholar 

  44. Shapiro J, Smith H, Schaffner F: Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979, 20:137–140.

    Article  PubMed  CAS  Google Scholar 

  45. Neuberger JM, Gunson BK, Buckels JAC, et al.: Referral of patients with primary biliary cirrhosis for liver transplantation. Gut 1990, 31:1069–1072.

    Article  PubMed  CAS  Google Scholar 

  46. Dickson ER, Grambsch PM, Fleming TR, et al.: Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989, 10:1–7.

    Article  PubMed  CAS  Google Scholar 

  47. Rydning A, Schrumpf E, Abdelnoor M, et al.: Factors of prognostic importance in primary biliary cirrhosis. Scand J Gastroenterol 1990, 25:119–126.

    Article  PubMed  CAS  Google Scholar 

  48. Christensen E, Altman DG, Neuberger J, et al.: Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993, 105:1865–1876.

    PubMed  CAS  Google Scholar 

  49. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, et al.: Is the Mayo model for predicting survival useful after introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996, 23:1148–1153.

    PubMed  CAS  Google Scholar 

  50. Poupon RE, Lindor KD, Cauch-Dudek K, et al.: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884–890. This analysis of the combined data of three large trials of UDCA therapy in patients with PBC demonstrates that long-term UDCA improves survival without liver transplantation in patients with moderate or severe disease.

    Article  PubMed  CAS  Google Scholar 

  51. Hendrickse M, Rigney E, Giaffer MH, et al.: Low-dose methotrexate in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Hepatology 1997, 26:248A.

    Google Scholar 

  52. Hubscher SG, Elias E, Buckels JAC, et al.: Primary biliary cirrhosis: histological evidence of disease recurrence after liver transplantation. J Hepatol 1993, 18:173–184.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Wisconsin, 9200 West Wisconsin Avenue, 53226, Milwaukee, WI, USA

    José Franco MD & Kia Saeian MD

Authors
  1. José Franco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kia Saeian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franco, J., Saeian, K. Biliary tract inflammatory disorders: Primary sclerosing cholangitis and primary biliary cirrhosis. Curr Gastroenterol Rep 1, 95–101 (1999). https://doi.org/10.1007/s11894-996-0006-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-996-0006-8

Keywords

Search

Navigation